AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Tetracaine hydrochloride works by blocking nerve signals in the body, temporarily numbing the area where it is applied or injected. It is commonly used to provide local anesthesia for procedures such as minor surgery, dental procedures, and certain medical tests or examinations.
Topical Application: Tetracaine hydrochloride is available in various forms for topical application, including creams, gels, solutions, and sprays. When applied to the skin or mucous membranes, it provides rapid and effective anesthesia to the targeted area.
Ophthalmic Use: Tetracaine hydrochloride is used in ophthalmology to numb the surface of the eye before procedures such as tonometry (measurement of intraocular pressure), foreign body removal, or eye examinations. It is typically administered as eye drops.
Dental Anesthesia: Tetracaine hydrochloride is commonly used in dentistry to numb the gums or oral mucosa before dental procedures such as tooth extraction, cavity filling, or root canal therapy. It may be applied as a topical gel or administered via injection.
Throat and Ear Anesthesia: Tetracaine hydrochloride may be used to numb the throat (e.g., for endoscopic procedures) or the ear canal (e.g., for ear examinations or the removal of impacted earwax).
Adverse Reactions: While tetracaine hydrochloride is generally considered safe when used as directed, some individuals may experience adverse reactions, particularly with prolonged or excessive use. Common side effects may include irritation, redness, burning sensation, or itching at the site of application. Allergic reactions are rare but can occur.
Systemic Toxicity: Tetracaine hydrochloride, like other local anesthetics, has the potential to cause systemic toxicity if absorbed in large amounts or if inadvertently injected into blood vessels. Symptoms of systemic toxicity may include dizziness, confusion, blurred vision, seizures, respiratory depression, and cardiac arrhythmias. Prompt medical attention is necessary if systemic toxicity is suspected.
Contraindications: Tetracaine hydrochloride is contraindicated in individuals with a known hypersensitivity to the drug or its components. It should be used with caution in patients with certain medical conditions, such as severe liver disease or cardiac conduction disturbances.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Morganellaceae | family | Decreases |
| 1 | 0 | Proteus | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | unclassified Proteus (in: enterobacteria) | no rank | Decreases |
| 0 | 1 | Proteus mirabilis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 0 | 1 | Proteus genomosp. 6 | species | Decreases |
| 0 | 1 | Proteus hauseri | species | Decreases |
| 0 | 1 | Proteus myxofaciens | species | Decreases |
| 0 | 1 | Proteus vulgaris | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Proteus terrae | species | Decreases |
| 0 | 1 | Proteus columbae | species | Decreases |
| 0 | 1 | Proteus penneri | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | -0.1 | |
| Allergies | 0.4 | 0.8 | -1 |
| Allergy to milk products | 0.4 | 0.4 | |
| Alzheimer's disease | 0.5 | 0.6 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.4 | 0.5 |
| Ankylosing spondylitis | 0.5 | 0.6 | -0.2 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Asthma | 0.3 | 0.2 | 0.5 |
| Atherosclerosis | 1.3 | 0.1 | 12 |
| Atrial fibrillation | 0.6 | 0.2 | 2 |
| Autism | 0.7 | 2 | -1.86 |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.3 | 0.3 | 0 |
| Brain Trauma | 0.5 | 0.3 | 0.67 |
| Breast Cancer | 0.8 | -0.8 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.6 | -0.6 | |
| Cerebral Palsy | 0.1 | 0.3 | -2 |
| Chronic Fatigue Syndrome | 0.5 | 0.3 | 0.67 |
| Chronic Kidney Disease | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Chronic Urticaria (Hives) | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.3 | 0.3 | |
| Colorectal Cancer | 1.1 | 1.1 | |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 0.4 | 1.3 | -2.25 |
| Crohn's Disease | 0.9 | 1.2 | -0.33 |
| deep vein thrombosis | 0.9 | 0.3 | 2 |
| Depression | 1.2 | 1.3 | -0.08 |
| Endometriosis | 0.6 | -0.6 | |
| Epilepsy | 0.1 | 0.2 | -1 |
| Fibromyalgia | 0.2 | -0.2 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.5 | 0.2 |
| gallstone disease (gsd) | 0.8 | 0.1 | 7 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.1 | 0.1 | 0 |
| Gout | 0.4 | 0.4 | 0 |
| Graves' disease | 0.3 | 0.3 | 0 |
| Gulf War Syndrome | 0.2 | -0.2 | |
| Hashimoto's thyroiditis | 0.4 | 0.3 | 0.33 |
| Heart Failure | 0.8 | 0.4 | 1 |
| Hidradenitis Suppurativa | 0.8 | 0.8 | |
| High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
| hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
| hyperglycemia | 0.6 | 0.2 | 2 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypertension (High Blood Pressure | 0.7 | 0.8 | -0.14 |
| Hypothyroidism | 0.6 | 0.6 | |
| Hypoxia | 0.1 | 0.2 | -1 |
| IgA nephropathy (IgAN) | 0.3 | 0.7 | -1.33 |
| Inflammatory Bowel Disease | 0.6 | 1.1 | -0.83 |
| Insomnia | 0.7 | -0.7 | |
| Intelligence | 0.2 | -0.2 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 1 | 0.7 | 0.43 |
| ischemic stroke | 0.4 | 0.4 | |
| Liver Cirrhosis | 0.4 | 1.1 | -1.75 |
| Long COVID | 0.8 | 1.3 | -0.63 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.4 | -0.4 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| Menopause | 0.1 | -0.1 | |
| Metabolic Syndrome | 0.4 | 0.5 | -0.25 |
| Mood Disorders | 1.3 | 0.7 | 0.86 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.5 | 1 | -1 |
| Multiple system atrophy (MSA) | 0.2 | 0.3 | -0.5 |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 1.2 | -0.5 |
| NonCeliac Gluten Sensitivity | 0.1 | 0.1 | |
| Obesity | 2.1 | 1.3 | 0.62 |
| obsessive-compulsive disorder | 0.4 | 0.3 | 0.33 |
| Osteoarthritis | 0.4 | -0.4 | |
| Osteoporosis | 0.3 | 0.1 | 2 |
| Parkinson's Disease | 1.9 | 0.8 | 1.37 |
| Polycystic ovary syndrome | 0.5 | 0.5 | 0 |
| Primary sclerosing cholangitis | 0.5 | 0.3 | 0.67 |
| Psoriasis | 0.4 | 0.3 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 2 | |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 0.7 | 0.6 | 0.17 |
| scoliosis | 0.5 | 0.8 | -0.6 |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 0.2 | 0.2 | |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.1 | 0.1 | 0 |
| Systemic Lupus Erythematosus | 0.6 | -0.6 | |
| Tic Disorder | 0.3 | 0.2 | 0.5 |
| Tourette syndrome | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.4 | 0.6 | -0.5 |
| Type 2 Diabetes | 0.4 | 0.5 | -0.25 |
| Ulcerative colitis | 0.8 | 0.7 | 0.14 |
| Unhealthy Ageing | 0.1 | -0.1 | |
| Vitiligo | 0.6 | 0.1 | 5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
